University of Groningen
Cardiovascular effects of non-cardiovascular drugs in heart failure
Yurista, Salva
DOI:
10.33612/diss.132706675
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Yurista, S. (2020). Cardiovascular effects of non-cardiovascular drugs in heart failure. University of Groningen. https://doi.org/10.33612/diss.132706675
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Cardiovascular effects
of non-cardiovascular drugs
in heart failure
Salva Reverentia Yurista received a PhD scholarship from the Indonesia Endowment Fund for Education (LPDP), Ministry of Finance, Republic of Indonesia.
Financial support by the Graduate School of Medical Sciences and University of Groningen for the publication of this thesis is gratefully acknowledged.
Financial support by Dutch Heart Foundation for the publication of the thesis is gratefully acknowledged.
Additional financial support for the publication of this thesis was provided by ChipSoft B.V., Servier Nederland Farma B.V., Boehringer Ingelheim B.V. and Pfizer B.V.
Cardiovascular effects of non-cardiovascular drugs in heart failure
Copyright © 2020 Salva R. Yurista
All rights are reserved.
No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form by any means, without permission of the author.
Cover and layout design by: Iliana Boshoven- Gkini | www.AgileColor.com Printing by: ProefschriftMaken
Cardiovascular effects
of non-cardiovascular drugs
in heart failure
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op woensdag 30 September 2020 om 09.00 uur
door
Salva Reverentia Yurista
geboren op 23 september 1990 te Probolinggo, Indonesië
Promotores
Prof. dr. R.A. de Boer Prof. dr. H.H.W. Silljé
Copromotor
Beoordelingscommissie
Prof. dr. C. Maack Prof. dr. J.F.C. Glatz Prof. dr. A.A. Voors
Paranimfen
Tim Eijgenraam Kirsten Nijholt
TABLE OF CONTENTS
Chapter 1 Introduction and aim of the thesis 11
Chapter 2 Sodium-glucose co-transporter 2 inhibition with empagliflozin
improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
European Journal of Heart Failure. 2019 Jul;21(7):862-873.
19
Chapter 3 Effects of sodium–glucose co-transporter 2 inhibition with
empaglifozin on renal structure and function in non-diabetic rats with left ventricular dysfunction after myocardial infarction Cardiovascular Drugs and Therapy. 2020 Jun;34(3):311-321
47
Chapter 4 Sodium-glucose co-transporter 2 inhibition as a mitochondrial
therapy for atrial fibrillation in patients with diabetes? Cardiovascular Diabetology. 2020 Jan 7;19(1):5
69
Chapter 5 Factor Xa inhibition with apixaban does not influence cardiac
remodelling in rats with heart failure after myocardial infarction Cardiovascular Drugs and Therapy. 2020 may 26. online ahead of print
81
Chapter 6 Ketone ester treatment improves cardiac function and reduces
pathologic remodeling in pre-clinical models of heart failure Manuscript in submission
101
Chapter 7 Ketone bodies: potential therapeutic use in cardiovascular disease
Manuscript in preparation
129
Chapter 8 Summary and future perspectives 149
Appendices Dutch summary 160
Acknowledgements 164
Bibliography 167
